Characterization of a pathogenic variant in GBA for Parkinson’s disease with mild cognitive impairment patients

Parkinson’s disease (PD) is the second most common neurodegenerative disease, and mild cognitive impairment (MCI) is a well-established risk factor for the development of dementia in PD. A growing body of evidence suggests that low expression of glucocerebrosidase ( GBA ) promotes the transmission o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular brain 2020-07, Vol.13 (1), p.1-102, Article 102
Hauptverfasser: Jiang, Zhiqiang, Huang, Yilin, Zhang, Piao, Han, Chongyin, Lu, Yueer, Mo, Zongchao, Zhang, Zhanyu, Li, Xin, Zhao, Sisi, Cai, Fuqiang, Huang, Lizhen, Chen, Chunbo, Shi, Zhihong, Zhang, Yuhu, Ling, Fei
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Parkinson’s disease (PD) is the second most common neurodegenerative disease, and mild cognitive impairment (MCI) is a well-established risk factor for the development of dementia in PD. A growing body of evidence suggests that low expression of glucocerebrosidase ( GBA ) promotes the transmission of α-synuclein (α-Syn) interpolymers and the progression of PD. However, how GBA mutations affect the pathogenesis of PD via abnormal aggregation of α-Syn is unclear, and no clinically valid PD-MCI genetic markers have been identified. Here, we first located a GBA eQTL, rs12411216, by analysing DHS, eQTL SNP, and transcription factor binding site data using the UCSC database. Subsequently, we found that rs12411216 was significantly associated with PD-MCI ( P  
ISSN:1756-6606
1756-6606
DOI:10.1186/s13041-020-00637-x